Haywood Brown, MD, immediate past president of the American College of Obstetricians and Gynecology (ACOG), discusses the importance of postpartum follow up, and the reasoning behind ACOG's recently revised committee opinion.
Transcript
ACOG recently released a revised committee opinion that proposes a new paradigm for postpartum care. What is the reason for this change?
Well this is something I’ve thought about for over a decade now— how we can improve the outcomes of women through postpartum follow up. And we’ve been stuck in the 6 weeks paradigm since the beginning of time, it seems. But really, it’s about seeing women when they need to be seen.
It’s very difficult to screen for postpartum depression if you don’t do it early. It’s very difficult to counsel women on breast feeding continuation if you don’t do it early. But once pregnancy complications occur— whether they be having a preterm baby or preeclampsia– the whole postpartum follow up really changes. The idea behind having an early visit and a later visit is so that you can discuss reproductive life planning and long-term health risks during that time period, over that 12 weeks.
Our whole objective is to do a better job with education of the patients, but also with the providers on the importance of postpartum follow up, and also guiding the principles for long-term health. That’s really the reason for the change, and that’s the reason that we proposed this for one of our task forces.
At ASCO, Testing and AI Rival Drugs for Attention, but Reimbursement Remains a Barrier
July 5th 2025Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage cancer care over time. A feature from our upcoming special issue of Evidence-Based Oncology: our annual ASCO recap.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity
July 1st 2025Joshua K. Sabari, MD, of NYU Langone Health discusses promising results for zongertinib in HER2-mutant NSCLC; the tyrosine kinase inhibitor offers high response rates and improved quality of life with minimal toxicity.
Read More